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Fig. 3. Se^egation of
BRCA2 mutant alíeles in
the EUFA423 pedigree.
(A) The proband with FA
subtype DI is EUFA423.
Cenomic DNA was pre-
pared from lympho-
Masts from the indicat-
ed family members
and was sequenced for
BRCA2 mutations. (B)
Expression of mutant
BRCA2 potypeptides in
lymphobtasts derived
from EUFA4Z3 kindred.
Proteins were immuno-
blotted with Ab-2.
(C) EUFA423F was
transfected either with
pcDNA3-empty vector
or pcDNA3-HA-BRCA2
{28. 29). and stable
G418-resistant cells were isolated. Cett tines were analyzed by immunoblot with Ab-2 and by the MMC
chromosome breakage assay (Table 2).
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cancer risk as high as 70% by age 70. Other
variant BRCA2 alíeles, sueh as the polymor-
phic stop codon ter3326, appear to cause no
increased cancer risk {¡H) but may cause FA
in the compound heterozygous state. The
smallest known cancer-associated deletion
removes only 224 amino acids from the
COOH-terminus of BRCA2 {24). Due to the
unavailability of clinical records, we were
unable to assess the cancer risk of the BRCA2
mutant alíeles in these FA families {Table 1).
FA patients with biailelie BRCA2 mutations
share clinical features with FA patients from
other subtypes (i.e.. amgenital abnormalities,
abnomial skin pigmentation, bone marrow fail-
ure, and cellular sensitivity to MMC) {25) (table
SI ). These similarities suggest that BRCA2 and
other FA proteins cooperate in a common DNA
damage response pathway, the FA/BRCA path-
way (Model, fig. S3A). According to this mod-
el, DNA damage activates the monoubiquitina-
tion of FANCD2, thus targeting FANCD2 to
DNA repair foci containing BRCA 1 and
BRCA2 {26). Previous studies have indieated
that FA-B cells laek FANCD2 monoubiquiti-
nation, whereas FA-Dl eells express monou-
biqiiitinated FANCD2 {8) (fig. S3B). BRCA2
may function upstream in the pathway, by pro-
moting FA eomplex assembly and FANCD2
activation, and/or downstream in the pathway,
by transducing signals from FA proteins to
RADS I and the homologous recombination
machinery {27). The precise molecular flinc-
non(s) of BRCAl and BRCA2 in this pathway
remain to be elucidated.
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Activation of Central
Melanocortin Pathways by
Fenfluramlne
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D-fenfluramine (d-FEN) was once widely prescribed and was among the most
effective weight loss drugs, but was withdrawn from clinical use because of
reports of cardiac complications in a subset of patients. Discerning the neu-
robiology underlying the anorexic action of d-FEN may facilitate the develop-
ment of new drugs to prevent and treat obesity. Through a combination of
functional neuroanatomy, feeding, and electrophysiology studies in rodents, we
show that d-FEN-induced anorexia requires activation of central nervous sys-
tem melanocortin pathways. These results provide a mechanistic explanation
of d-FEN's anorexic actions and indicate that drugs targeting these downstream
melanocortin pathways may prove to be effective and more selective anti-
obesity treatments.
Drugs that increase the activity of central
serotonin (5-hydroxytryptamine, 5-HT) have
been widely used as appetite suppressants
{1-3). However, these drugs often elieit un-
wanted side effects because they target mul-
tiple 5-IIT pathways and receptors. A notable
exatnple is d-FEN. a drug that blocks the
reuptake of 5-HT and stimulates its release
(.Ï). In the mid-1990s, d-FEN was prescribed
to millions of people in the United States for
weight loss, frequently in combination with
the sympathomimetic phentemiinc, but was
www.sciencemag.org SCIENCE VOL 297 26 JULY 2002 609
R E P O R T S
withdrawn from clinical use in 1997 by the
Food and Drug Administration after reports
of adverse cardiopulmonary events {4).
Delineation of the central nervous system
(CNS) pathways through whieh d-FEN me-
diates its effects on food intake may lead to
the development of new appetite suppressant
drugs that have fewer side effects. As a first
step toward this goal, we perfonned a dose-
response study to identify a threshold dose of
d-FEN (Sigma) that reduced feeding behavior
in rats without inducing other gross behav-
ioral abnormalilies (fig. SI) (5). We used
Fos-like immunoreactivity (FOS-IR) to cor-
relate anorexic efficacy with neuronal activa-
tion patterns in the brain {6). As previously
reported, d-FEN induced FOS-IR in a dose-
dependent manner in many brain regions as-
sociated with energy homeostasis (7), includ-
ing the arcuate nucleus of the hypothalamus
(ARC) and the para ventricular nucleus of the
hypothalamus (PVN). ARC FOS-IR expres-
sion was most prominent in the lateral re-
gions, where pro-opiomelanocortin (POMC)
neurons reside. These neurons are a potential
target for d-FEN action because they receive
direct input from 5-HT dorsaJ raphe nucleus
neurons (8) and project to regions associated
with energy regulation (9-11).
To determine whether d-FEN activates
POMÇ neurons, we performed dual-labeling
immunohistochemieal experiments using an-
tisera to a-melanocyte stimulating hormone
(a-MSH). a POMC-derived anorexic peptide.
Threshold anorexic doses of d-FEN signifi-
cantly and consistently induced FOS-IR in
a-MSH-immunoreactive (a-MSH-IR) neu-
rons throughout the ARC [average coexpres-
sion, d-FEN = 45%, saline - 14%; /(6) -
14.9, P < 0.001] (Fig. 1, A to C). A similar
pattem of d-FEN-induced FOS-IR was ob-
served in ARC eells expressing POMC
mRNA {¡2). These data strongly suggest that
threshold anorexic doses of d-FEN activate
POMC neurons in the ARC.
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We hypothesized that 5-HT receptors (5-
lITRs) are expressed in POMC neurons and
that action at these receptors mediates a
component of the anorexic effeet of d-FEN.
5-HT2cRs, formerly called 5-HT,ç.Rs, are a
strong candidate for this action because
they are expressed in the ARC {13). More-
over. 5-HT2(.R-deficient mice are hy-
perphagie, obese, and refractory to thresh-
old anorexic doses of d-FEN {¡4. 15). We
found that up to 80% of a-MSH neurons
express 5-HT2(.R mRNA (Fig. 1, D to F)
and that the pattem of coexpression was
greatest in the caudal ARC.
If d-FEN exerts its anorexic effect
through action at 5-HT2t-Rs, then direct
activation of 5-HT2(-Rs should mimic the
effects of d-FííN. Indeed, rats treated with
the 5-HTif.,,uR agonist l-{m-chlorophe-
nyOpiperazine (mCPP, Sigma) decreased
their acute food intake (fig. SI ) and showed
increased induction of FOS-IR in a pattem
consistent wilh d-FEN-induced FOS-IR
expression in the ARC and PVN (fig. S2).
Moreover, threshold anorexic doses of
mCPP [5.0 mg/kg intravenously (iv)] in-
duced similar significant FOS-TR in
a-MSH neurons in the ARC [average co-
expression, mCPP ^ 54%, saline = 14%;
/(5) = 15.8, P < O.OOI]. These data indi-
cate that d-FEN and mCPP-indueed FOS-
IR in POMC neurons may involve activa-
tion of 5-HT^^.Rs.
To investigate whether d-FEN directly
activates POMC neurons, we performed
eleetrophysiology studies on hypothalamic
slices from transgenic mice expressing
green fluorescent protein (GFP) under con-
trol of the POMC promoter (5. 16). d-FEN
induced a doubling of the spontaneous
firing rate in POMC neurons, an effect
reversed by drug washout (Fig. 2A). More-
over, POMC neurons depolarized in re-
sponse to administration of d-FEN, 5-HT,
or two 5-HT2<^ .R agonists, mCPP and MK
212 (Fig. 2B). These data support the no-
tion that central 5-HT systems directly ac-
tivate POMC neurons.
On the basis of these findings., we hy-
pothesized that d-FEN stimulates the re-
lease of 5-HT in the ARC and that the
neurotransmitter then hinds to 5-HTj^.Rs
Fig. 1. d-FEN activates ARC «-MSH neurons tbat express 5-HT Rs. Pathogen-free adult male
Sprague-Dawley rats (n = 3 to 6 per group; 250 to 325 g) were individually housed with water and
rat cbow pellets available ad libitum in a light-controlled (12 hours on/12 hours off) and
temperature-controlled environment [21.5" to 22.S''C {26)]. Rats were perfused and brains were
processed for histochemistry (6). Multiple markers for «-MSH-expressing neurons were examined
[rt-MSH-IR, CART-IR, and "S-labeled POMC cRNA riboprobe (9)] for coexpression with FOS-IR or
5-HT,ç.R mRNA. Eacb combination assessed yielded comparable results. Data were collected from
four levels of the ARC, which were identified on the basis of expression patterns of cellular
neurochemicat markers detailed in a rat brain atlas [atlas fig. 27 = ARC 1; atlas fig. 30 = ARC 2;
atlas fig. 33 = ARC 3; atlas fig. 37 = ARC 4; 3v, third ventricle (6, Z7)]. Examples of «-MSH
coexpression patterns witb FOS-IR and S-HT^ -^R mRNA in ARC 2 and ARC 4 were transposed into
drawings by concurrently visualizing brain sections with a lOx objective of a microscope and a
computer screen. The architecture and marker expression of the cells was then transposed into a
drawing. (A and B) Rats were injected witb d-FEN (1.0 mg/kg, iv). Two hours later, rats were
perfused and brains were removed. FOS-IR ( ), a-MSH (D). and coexpression of FOS-IR and «-MSH
(red stars) are sbown at ARC 2 and ARC 4 levels. d-FEN significantly induced FOS-IR in u-MSH
neurons at all four levels of the ARC compared to saline treatment (P < 0.001). (C) «-MSH-IR
neurons (brown cytoplasm) contain FOS-IR (black nuclei). (D and E) a-MSH neurons express
5-HT2cR mRNA [S-HT^^R riboprobe was described in (28)]. »-MSH (O), S-HT^^R (•}. and
coexpression of «-MSH and S-HT^ -^R (red stars) are sbown at ARC 2 and ARC 4 levels. (F) a-MSH-IR
neurons (brown cytoplasm) contain ^%-labeled 5-HT,,Rs (cluster of black grains). Scale bar, 10 \xn\
(C. F).
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expressed in POMC neurons. This in tum
could stimulate the release of u-MSH,
which acts on effector neurons expressing
melanocortin 4 receptors (MC4-R) and
melanocortin 3 receptors (MC3-R). MC4-
Rs have been identified as critical regula-
tors of food intake, energy expenditure, and
neuroendocrine function [e.g., (17-20)].
MC3-Rs have also been implicated in en-
ergy homeostasis {21, 22). To test whether
d-FEN
200 400 600 800 10001200
Time (s)
^ J. 10oa
20 30 2 4 30
5-HT & 5-HT Drugs
Fig. 2, 5-HT drugs increase the frequency of
action potentials and depolarize POMC cells.
Standard electrophysiological techniques
were applied to coronal slices of hypothalami
from male POMC-EGFP transgenic mice (20
to 25 g) (5. 16. 26). (A) Using a ¡oose-cell-
attached mode, d-FEN (20 M-M) induced a
doubling of the mean (±SEM) POMC neuron
firing rate {n = 3), This effect was reversed
with drug washout. (B) Mean (±SEM) peak
depolarization of POMC-EGFP neurons (n = 4
to 8 per dose) bathed with 20 M,M d-FEN
(black bar), 30 ^iM 5-HT (hatched bar; Sig-
ma), Z or A (i,M mCPP (white bars), or 30 or
50 fj.M MK 212 (gray bars; Sigma), using a
conventional whole-cell mode (*? < 0,05),
genetic or pharmacological bloekade of
MC4-Rs/MC3-Rs reduces the anorectic ef-
ficacy of d-FEN. we administered d-FEN to
A^ mice, an obese strain resulting from
ectopic overexpression of agouti, an endog-
enous melanocortin receptor antagonist
{23-25). We observed ihai young A^ mice
exhibited significantly attenuated responses
to the anorexic actions of d-FEN compared
to wild-type littermates (Fig. 3A). Similar-
ly, we found that administration of the
MC4-R/MC3-R antagonist SHUi^lW to
rats before d-FEN significantly decreased
the anorexic response to d-FEN (Fig. 3B)
(25). Thus. MC4-Rs/MC3-Rs are likely
downstream mediators of d-FEN-activated
neurons.
To confirm that S-HT i^^ R action on
POMC neurons is upstream of MC-Rs, we
administered the MC4-R/MC3-R agonist
MT II [ 1 nmol intracerebroventricularly
(lev)] to 5-HT,ç.R-deficient mice and wild-
type littermates before divergence of body
weight (5), Relative to mice given vehicle
alone, treatment wilh MT II caused a sig-
nificant reduction in food intake up to 8
hours after injection. No differences in
food intake at vehicle or drug treatment
were observed between genotypes, nor
were there genotype-specific differences in
baseline POMC mRNA expression in the
ARC (fig. S3),
Our data show that components of the
anorexic effects of d-FEN are mediated
through the central melanocortin system,
which is now well established as a funda-
mental regulator of food intake and body
weight in rodents and humans. d-FEN is an
indirect 5-HT agonist, thereby increasing
5-HT activity throughout 5-HT pathways in
the CNS. It is noteworthy that our findings
indicate that genetic or pharmacological
blockade of MC4-Rs/MC3-Rs is sufficient
to attenuate the anorectic efficacy of
— 15
3
0.5
00 I1Í
0 3.0
d-Fenfluramine (mg/kg)
Fig. 3. Melanocortin receptor an-
tagonists attenuate tbe anorec-
tic effect of d-FEN. (A) Male A^
mice (black bars) and their wild-
type littermates (white bars) (4
weeks old, Jackson Laboratories)
were individually boused as de-
scribed in Fig. 1 (26). Mice were
treated with d-FEN [0 or 3.0 mg/
kg intraperitoneally (ip)] at tbe
onset of the dark cycle and wet
chow masb intake was measured
50 min after treatment (75), d-
FEN significantly reduced mash intake In wild-type but not A^ mice (*P < 0,05). No differences In
mash intake were observed after saline treatment, (B) Rats, housed as described in Fig, T, were
stereotaxically implanted with a guide cannula aimed at tbe tbird cerebral ventricle [1,5 to 2 mm
posterior to bregma in tbe midline and 8 to 8,2 mm below the skull surface {25, 26)], Two weeks
later, rats were fasted for 16 bours with water available ad libitum. Animals (n = 5 to 6 per group)
were pretreated witb saline or 5HU9n9 (0.3 nmol icv; Phoenix Pharmaceuticals) and treated with
saline or d-FEN (1 mg/kg ip). Intake of rat chow pellets was measured for tbe next hour. Animals
pretreated with vehicle and treated with d-FEN showed significant reductions in food intake {P <
0.001), However, pretreatment witb SHU9119 significantly attenuated d-FEN-induced anorexia
[**P < 0.01). SHU9119 did not alter food intake when given alone.
threshold doses of d-FEN. Our results sug-
gest that drugs targeting these downstream
melanocortin pathways may act in part in a
similar manner to d-FEN to decrease food
intake and body weight, and may yield
fewer 5-Hr-related side effects. Finally,
these data indicate that 5-HT,j-,Rs are ex-
pressed on many POMC neurons, and add
the CNS 5-HT .system to the growing list of
metabolic signals that converge on melano-
cortin neurons in the ARC,
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